LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Listă Acțiuni・IQVIA Holdings Inc

IQVIA Holdings Inc

Deschisă

Sector Sănătate

209.62 0.21

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

204.7

Maxim

210.76

Indicatori cheie
By Trading Economics
Venit	-78M 285M
Vânzări	90M 3.9B
P/E Medie Sector	28.89 104.138
EPS	2.84
Marjă de profit	7.308
Angajați	87,000
EBITDA	-12M 856M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+24.53 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-4.9B 37B
Deschiderea anterioară	209.41
Închiderea anterioară	209.62

Sentimentul știrilor

By Acuity

50%

167 / 390 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

200.3 / 214.63 Suport & Rezistență

IQVIA Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 nov. 2024, 23:05 UTC

Top știri

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3 nov. 2024, 21:12 UTC

Câștiguri

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3 nov. 2024, 20:59 UTC

Câștiguri

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3 nov. 2024, 23:34 UTC

Top știri

Stocks Poised for Lower Open -- Barrons.com

3 nov. 2024, 23:16 UTC

Top știri

Câștiguri

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3 nov. 2024, 22:50 UTC

Achiziții, Fuziuni, Preluări

Santos Says Working Interest in PNG LNG Now 39.9%

3 nov. 2024, 22:50 UTC

Achiziții, Fuziuni, Preluări

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3 nov. 2024, 22:49 UTC

Achiziții, Fuziuni, Preluări

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3 nov. 2024, 22:49 UTC

Achiziții, Fuziuni, Preluări

Santos Receives Final $241 Million Payment From Kumul

3 nov. 2024, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3 nov. 2024, 20:36 UTC

Câștiguri

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac Raises Share Buyback Program by A$1 Billion

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac Final Dividend A$0.76/Share

3 nov. 2024, 20:33 UTC

Câștiguri

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3 nov. 2024, 20:32 UTC

Câștiguri

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3 nov. 2024, 20:32 UTC

Câștiguri

Westpac FY Net Profit A$6.99 Billion, Down 3%

3 nov. 2024, 18:09 UTC

Top știri

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3 nov. 2024, 10:30 UTC

Top știri

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3 nov. 2024, 03:00 UTC

Top știri

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2 nov. 2024, 13:53 UTC

Top știri

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov. 2024, 13:44 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 13:00 UTC

Top știri

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov. 2024, 12:58 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:48 UTC

Top știri

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov. 2024, 12:32 UTC

Câștiguri

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Comparație

Modificare preț

IQVIA Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

24.53% sus

Prognoză pe 12 luni

Medie 260.46 USD 24.53%

Maxim 279 USD

Minim 235 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIQVIA Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor IQVIA Holdings Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

200.3 / 214.63Suport & Rezistență

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

167 / 390 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre IQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.